Category Archives: Psoriasis

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model

IND submission for brilaroxazine lipogel in psoriasis expected in 2024

Reviva has filed composition of matter patent for brilaroxazine-lipogel and a separate patent for use in the treatment of psoriasis

Preclinical efficacy data presented at the ISID 2023 meeting

CUPERTINO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Company), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan, May 10-13, 2023. The ISID poster is available at revivapharma.com/publications.

The multifaceted activity of brilaroxazine offers the promise to improve the quality of life and provide a novel treatment option for patients with psoriasis, an inflammatory condition stemming from serotonin and dopamine dysfunction, said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. We were excited to present encouraging preclinical data at ISID 2023 highlighting the therapeutic potential of brilaroxazine lipogel, a novel, proprietary lipogel formulation for the topical treatment of psoriasis. We have filed a composition of matter patent for brilaroxazine-lipogel and a separate patent for its use in psoriasis. Mental illness, including schizophrenia and depression, is a major comorbidity in patients with psoriasis. Brilaroxazine has established a well-tolerated safety profile with robust efficacy in about 300 patients with schizophrenia from Phase 1B and Phase 2 studies. To further explore this therapeutic potential, we intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.

Psoriasis is a chronic dermal inflammatory disease with a global prevalence of ~125 million. Dopamine (D) and serotonin (5-HT) signaling pathways play an important role in the pathobiology of psoriasis, and lead to increased inflammatory mediators (TNF-, IFN-, IL-1, IL-6, IL-8), keratinocyte activation and deterioration, and worsening symptoms. Current treatments include multiple modalities but are limited by long-term side effects (topicals), toxicities (orals) or risk of immunogenicity, serious infection, and malignancy (biologics). Brilaroxazine (RP5063) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology. Preclinical studies in the imiquimod-induced psoriatic mouse model (BALB/c) were used to evaluate the potential of topical liposomal-gel formulation of brilaroxazine for the treatment of psoriasis.

Key poster highlights support the therapeutic potential of brilaroxazine lipogel in psoriasis:

2023 GlobeNewswire, Inc., source Press Releases

Read more from the original source:
Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com

During this HCPLive interview, Adam Friedman, MD, spoke on concerns about disparities between different groups with atopic dermatitis and the ways in which he hopes to address them.

Friedmans discussion was the result of his presentation from the Revolutionizing Atopic Dermatitis (RAD) 2023 Annual Meeting in Washington, DC., during which he presented on Using teledermatology to reduce disparities in atopic dermatitis care.

He is known for his work as Professor and Chair of Dermatology in the Department of Dermatology at the George Washington University School of Medicine & Health Sciences.

I think there's certainly more global disparities, he explained. And there are a lot of different reasons for them. I think that they range from when we say access, that can mean a lot of things. It can mean having a physician or a specialist in your area that you can physically access or even if you do, can you even get into see that person because they're so overwhelmed with patients, does it mean that you can physically get there, (or) whether you have the means to get to a visit?

He added that there are disparities between different populations, noting that there are many different subgroups and variables.

But we do see with atopic dermatitis, for example, those who identify as black depending on certain studies or African Americanoften those terms are put side by side and they're not the same, but that's what we seethat there is a higher prevalence of disease, more severe disease, he said. But those individuals make up a very small subset of those who are actually being seen by dermatologists.

Friedman added that dermatologists know that socioeconomic status is an independent risk factor for more severe and uncontrolled diseases.

So I think there's a lot more to learn and I think the way we solicit information will ultimately lend itself to better understanding the needs of specific communities and populations, he explained. But certainly from the information we have, there are those who seem to be at higher risk for all the horrific primary and secondary things that atopic dermatitis can cause and lead to down the road.

For more information about Friedmans presentation, view the full interview segment above.

Read more here:
Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine

Epilepsy should be added to the list of neurological outcomes following an infection of invasive Group BStreptococcus(iGBS)particularly meningitisin early infancy, new study results suggest.

Findings from a population-based cohort study, published in JAMA Network Open, revealed iGBS disease was linked with a higher incidence of epilepsy in later childhood, notably after meningitis. The risk of epilepsy in later childhood was higher among those born prematurely, males, or those born to a mother belonging to a low socioeconomic position (SEP).

iGBS disease is a leading cause of neonatal and young infant mortality around the world. In 2020, it was estimated that 500,000 cases of iGBS disease occurred within the first 3 months after birth, the authors wrote.

Although epilepsy has been reported as an outcome following iGBS disease, particularly meningitis, the risk of the condition after neonatal iGBS disease has yet to be investigated further, the researchers said. To address this knowledge gap, they studied children with iGBS born in Denmark between 1997 and 2017. Follow-up continued until the end of 2018.

A total of 1432 children with iGBS disease (sepsis, n = 1264; meningitis, n = 168) were included in the study and compared with 14,211 unaffected children. All participants were aged between 0 and 89 days, 55.3% were male, and nearly 79% had a gestational age of at least 37 weeks. The mothers SEP was determined via income and education level.

Analyses revealed:

Overall, we found a significantly higher risk of epilepsy in children with iGBS meningitis in later childhood compared with children not exposed to iGBS, the authors wrote. The risk of epilepsy for iGBS sepsis was not significant.

Compared with those without iGBS, the cumulative incidence of epilepsy was higher within the first 5 years after diagnosis of iGBS.

To the authors knowledge, the study is the first to examine the long-term risk of epilepsy as an individual outcome after iGBS sepsis or meningitis.

The large cohort of children with iGBS disease and comparison group, in addition to long-term follow-up until adolescence, mark strengths of the current investigation. Researchers were also able to match groups on all matching variables with small differences between cohorts, helping to reduce residual confounding.

However, data for iGBS onset were defined based on admission date, meaning the study may have excluded iGBS infections from the day of birth. Results should also be interpreted with caution, due to the small size of the iGBS meningitis cohort, the authors noted. Data also did not account for childhood accidents, infectious diseases, or head trauma that took place after the index date.

Our findings have implications for estimating the global burden of iGBS and should be considered in relation to the cost-effectiveness of interventions, such as intrapartum antibiotic prophylaxis and maternal vaccination, the authors concluded. Importantly, these data also have implications for affected individuals and underline the need for better long-term follow-up and care.

Reference

Lykke MR, Srensen HT, Lawn JE, Horvth-Puh E. Long-term risk of epilepsy following invasive group B Streptococcusdisease in neonates in Denmark. JAMA Netw Open. Published online April 21, 2023. doi:10.1001/jamanetworkopen.2023.9507

Read the original:
Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network

By John Vandermosten, CFA

NASDAQ:NOVN

READ THE FULL NOVN RESEARCH REPORT

1Q:23 Financial and Operational Results

On May 15th, 2023, Novan Inc. (NASDAQ:NOVN) reported 1Q:23 financial and operational results in a press release and in the filing of Form 10-Q. A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the EPI Health assets and efforts related to SB206s New Drug Application (NDA) which has been assigned a target action date of January 25th, 2024. Novan is increasingly focused on potential funding or strategic arrangements and alternatives to address short-term cash needs and access to capital is necessary to progress development of SB206. Since the report of 2022 results in late March, Novan held an analyst and investor day and announced a publication supportive of patient use of Wynzora.

Highlights for 2023 include:

SB206 NDA submitted for molluscum contagiosum January 2023

NDA accepted for SB206 assigning 5JAN24 PDUFA date March 2023

$6 million registered direct offering March 2023

Investor KOL event with Dr. Sugarman on molluscum unmet need April 2023

Publication of survey on patient needs for psoriasis medication April 2023

With respect to financial performance, Novan generated $3.2 million in 1Q:23 revenues versus $1.9 million in 1Q:22, and posted a net loss of ($14.1) million or ($0.54) per share compared to a loss of ($13.4) million or ($0.71) per share in the prior year period.

For the quarter ending March 31, 2023 and versus the same prior year period:

Revenues were $3.2 million, up 64% from $1.9 million. The increase is predominantly due to revenue contribution from sales of dermatology products Wynzora, Rhofade, Minolira and Cloderm and recognition of a full quarter of sales in 1Q:23 compared with 20 days of sales in 1Q:22. Year over year increases were tempered by Rhofade suffering a manufacturing delay which led to a to lack of inventory and loss of sales in 1Q:23; however, management noted that a rebound in orders was experienced in the second quarter as units were restocked. Furthermore, deductible resets for 2023 contributed to the sequential slowdown in scripts and revenues for Novans three leading products.

Story continues

License and collaboration revenues of $585,000 were down 50% due to the absence of revenues from the distribution and supply agreement for Cloderm. Research and grant revenues were up 370% to $170,000 from $36,000 on recognition of multiple federal grants;

Cost of goods sold was $1.3 million vs. $0.2 million;

Research & development expenses totaled $4.8 million, essentially flat with prior year levels. Declines in spending on the SB206 program were offset by increases in other research and development expenses related to a $1 million milestone payment to Ligand;

Selling, general & administrative expenses were $10.0 million, also flat with prior year amounts. 1Q:22 expenses related to the EPI acquisition were replaced by greater commercialization spending for the product portfolio in 1Q:23;

Net loss was ($14.1) million, or ($0.54) per basic and diluted share, compared to ($13.4) million, or ($0.71) per share.

As of March 31, 2023, cash and equivalents on the balance sheet totaled $12.5 million. This compares to cash holdings of $12.3 million at the end of 2022. Cash burn was ($4.3) million which was partially offset by $4.1 million of net contributions from financing. $6.0 million of this amount was from the direct offering which was executed in mid-March. $5.0 million was also received from Sato related to the license agreement for Rhofade. $1.25 million of the Sato/Rhofade upfront is owed to a third party tempering the impact from this cash flow. Novan anticipates that there is sufficient liquidity to support operations until late second quarter 2023.

Corporate Updates

Psoriasis Publication

Findings from a National Psoriasis Foundation study were published in the Journal of Drugs in Dermatology which surveyed more than 400 US patients on patient adherence to topical psoriasis medications. The title of the April 2023 publication is Patient Preferences in Topical Psoriasis Treatment by Curcio, et al.1 The 17-question survey was administered in March 2022 and queried participants on psoriasis severity, bothersome signs and symptoms, current treatment modalities, frequency of topical therapy use, and vehicle preferences.

84% of the participants reported moderate psoriasis with 72.5% of participants using oral medication and 8% topical treatment alone. 76% used topical therapy at least once weekly and 80% reported that they would wait two weeks after starting a new topical treatment before considering discontinuation. Participants preferred water-based creams (75.7%), followed by oil-based foam (70.8%), gel (48.7%), solution (42.8%), lotion (21.2%), non-oil-based foam (17.5%), ointment (16.5%), and spray (6.3%). Other desirable features were formulas that did not stain, were absorbed quickly, were not sticky and were easy to apply. 75% said they would continue to use a psoriasis medication for a week before stopping if they didnt like its topical formulation.

Novans press release continued with a summary of Wynzoras features. Novans product, which is commercialized jointly with MC2 Therapeutics, offers a rapid onset of action with results seen in efficacy, scale and itch as early as one week after application and continued improvement at 8 weeks. Additional detail on Wynzoras profile are included in an analysis by Han, et al.2 and in the products label.

A Discussion of Molluscums Unmet Need

Novan held a stakeholder event on April 25th, 2023 featuring pediatric dermatologist Jeffrey Sugarman, MD, PhD to discuss molluscums unmet need with investors and analysts. The presentation began with an introduction by CEO Paula Brown Stafford who summarized the companys pipeline and the status of lead candidate SB-206, which is now being considered for approval by the FDA. She was followed by Chief Commercial Officer Brian Johnson who quantified the unmet need for molluscum patients. Existing options for patients include potentially painful in-office procedures and non-approved approaches that have limited efficacy. Health care providers (HCPs) want to see solutions for MC and are willing to prescribe an effective medicine if available.

To provide the HCP perspective, pediatric dermatologist Dr. Jeffrey Sugarman was featured who also served as the safety monitor for the Phase III clinical trials for SB-206. MC is commonly seen in children from 3 to 8 years of age, but does move outside of this range. Children with MC frequently also experience eczema, which can make the disease uncomfortable in addition to unsightly and contagious. Dr. Sugarman identified some of the features that physicians would like to see in an MC treatment. These include a safe, effective and well-tolerated product that is convenient to use. SB-206 achieves these objectives for patients, including convenience as it is a prescribed product that can be used at home.

Further discussion detailed the manufacturing and commercialization activities that have been taking place and that will take place over the next quarters. Pediatric dermatologists and primary care pediatricians will be the target audience for the anticipated marketing effort. The panel participants brought up the pending target action date for Verricas cantharidin treatment for MC which is in late July. Having two companies commercializing simultaneously could be beneficial for educating providers on the available options.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

________________________

1. Curcio, A., et al. Patient Preferences in Topical Psoriasis Treatment. Journal of Drugs in Dermatology, April 2023.

2. Han, G., Feldman, S., Bhatia, N., & Prstegaard, M. (2022). Dipropionate (Bdp) Cream (Cal 0.005%/Bdp 0.064% W/W) Improves Plaque Psoriasis At Week One In A Phase 3 Trial. SKIN The Journal of Cutaneous Medicine, 6(4), s42. https://doi.org/10.25251/skin.6.supp.42

Continue reading here:
NOVN: Counting Down to PDUFA - Yahoo Finance

In 2022, the global Psoriatic Arthritis (PsA) Treatment Market sales is expected to exceed US$ 10.3 billion. The market is expected to reach US$ 15.6 billion by 2028, growing at a strong 7.1% CAGR.

According to Future Market Insights, the Psoriatic Arthritis (PsA) Treatment Market would grow at a 7.1% CAGR between 2022 and 2028, up from a 6.7% CAGR between 2013 and 2021.

According to the Arthritis Foundation, nearly 70% of psoriasis patients are predisposed to psoriatic arthritis, and up to 20% of arthritis patients are predisposed to psoriasis.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2718

In recent years, the increasing burden of psoriasis and psoriatic arthritis on the healthcare industry has boosted clinical research in the field of psoriatic arthritis.

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand forpsoriatic arthritis treatmentin coming years.

Role of Strong Product Pipeline & Mounting Clinical Research Investments

According to the National Psoriasis Foundation, around 20 medicines for psoriasis and psoriatic arthritis are now in phase II clinical trials, with another 28 in phase III. However, around 24 medicines have already been approved by the FDA for use in the treatment of psoriasis and psoriatic arthritis.

While a solid product pipeline continues to boost demand for psoriasis and psoriatic arthritis treatment, recent data indicates that numerous drug manufacturers are moving their focus to competitive pricing methods in an effort to achieve general adoption in the future years. Future Market Insights recently published new insight based on its analysis of the worldwide psoriatic arthritis therapy market. According to the analysis, the market would grow at a rate of more than 7% per year by 2022.

Industry Behemoths Cover More than 55% Market Value Share

In a largely consolidated worldwide landscape of psoriatic arthritis treatment market, industry giants such as Novartis AG and AbbVie Inc., which include biologics in their core portfolio, account for more than 55% of total revenue. While market leaders continue to focus on FDA clearances and clinical trials, data indicates that different pricing strategies are becoming increasingly important.

Get in Touch With Our Team For Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-2718

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape, says a senior research analyst at the company.

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4thof the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North Americas market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europes market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

Request Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-2718

Psoriatic Arthritis (PsA) Treatment Market by Category

Product Type:

Route of Administration:

Distribution Channel:

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware 19713, USAT: +1-845-579-5705For Sales Enquiries:sales@futuremarketinsights.comBrowse All Reports:https://www.futuremarketinsights.com/reportsLinkedIn |Twitter |Blogs

View post:
Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights

Topical steroid withdrawal TSW campaign launched to raise awareness in eczema and psoriasis sufferersTo raise awareness of Topical Steroid Withdrawal (TSW), bath salt brand Westlab has announced its TSW Awareness Campaign.

The campaign is targeted towards those who suffer from TSW, including parents and carers of those with the condition.

It has been developed alongside experts to raise awareness of the urgent need for research to aid GPs, pharmacists, and dermatologists in diagnosing and treating their patients safely, while helping prevent the long-term risks of topical steroid misuse.

Topical corticosteroids, a steroid treatment applied directly to the skin, help reduce inflammation and irritation for conditions such as eczema and psoriasis. When used continuously over long periods of time, the body can become dependent.

TSW refers to the symptoms that occur when a patient reduces or ceases the use of topical steroids, including painful redness, burning, swelling, itching, flaking, and oozing of the skin.

Not only is this extremely painful for the patient, but it can also lead to mental health issues such as depression, insomnia, anxiety, and PTSD.

With limited research around TSW and no definitive NHS guidelines for GPs and dermatologists to follow in supporting their patients, one of the main aims of Westlabs campaign will be education to help prevent accidental misuse or prescription of corticosteroids.

The campaign will also see Westlabeducate TSW parents with digestible bite-size information on managing childhoodeczema and psoriasismore naturally, protecting the skin barrier right from the outset of triggers to avoid TSW.

The brand will donate 1,000kg of Dead Sea Salts to the TSW community, providing support to those starting on their journey and those who are acutely in need of relief.

Through expert panels and sponsorship, the brand says it will also dedicate its time and expertise to educate skin care specialists and pharmacists around the UK.

Westlab's campaign will aim to prevent future generations from experiencing the devastating physical and psychological effects of TSW, says the brand.

Anecdotal evidence suggests that soaking in a salt bath may help reduce the severity ofeczemasymptoms,particularly in cases of oozing a lot or where secondary infection is common.

Westlab says that their microbiome-gentle Dead Sea Saltshelp to soothe, protect and repair the skins natural barrier, which is essential for eczema,psoriasis and recovery from TSW.

This is thanks to the abundance of minerals within them, inparticular magnesium, calcium and potassium.

View post:
New campaign raises awareness of topical steroid withdrawal - Professional Beauty

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa  Marketscreener.com

Read the rest here:
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in...

EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K)  Marketscreener.com

View post:
EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -...

Psoriasis is a recurring autoimmune disorder that affects more than 7.5 million American adults.

It tends to appear pink or red, usually with silvery-white scales, on those that have fair to light skin tones. On medium skin tones, it may look salmon-colored with a silvery-white scale, and on darker skin tones, it could look violet and the scale gray. Or it can also appear dark brown and difficult to see.

Even though it affects your skin, psoriasis actually begins inside your body in your immune system.

Psoriasis is a condition where your T-cells, a type of white blood cell, can become overactive to produce other immune markers that can cause an inflammatory reaction on the skin. The reaction on the skin shows up in the form of silvery-white scale, depending on the skin ton

Even though theres no cure, many treatments exist to ease the symptoms of psoriasis. Here are 12 ways to manage mild symptoms at home.

Dietary supplements may help ease psoriasis symptoms from the inside.

Fish oil, vitamin D, milk thistle, aloe vera, Oregon grape, and evening primrose oil have all been reported to help ease mild symptoms of psoriasis, according to the National Psoriasis Foundation.

Check with your doctor before taking supplements to make sure they dont interfere with other health conditions you may have or medications youre taking.

Use a humidifier to keep the air in your home or office moist. This can help prevent dry skin before it starts.

Moisturizers for sensitive skin can keep your skin supple and moisturized.

Aloe vera has been shown in some cases to reduce redness and irritation caused by psoriasis. A 2010 study found aloe vera gel cream to be slightly more effective in improving psoriasis symptoms compared to 0.1 percent triamcinolone acetonide, a steroid cream used to treat psoriasis.

More research is needed to show for sure if aloe vera can improve symptoms of psoriasis. However, the risk of trying aloe vera gels or creams is low, so it may be worth a try.

Most soaps and perfumes have dyes and other chemicals in them that may irritate your skin. They can make you smell great, but they also can inflame psoriasis.

Avoid such products when you can, or choose those with sensitive skin labels.

Diet may play a role in managing psoriasis.

Limiting red meat, saturated fats, refined sugars, carbohydrates, and alcohol may help reduce flare-ups triggered by such foods.

Cold water fish, seeds, nuts, and omega-3 fatty acids are known for their ability to reduce inflammation. This can be helpful for managing psoriasis symptoms.

Olive oil may also have soothing benefits when applied topically to the skin. Try massaging a few tablespoons on your scalp to help loosen troublesome plaques during your next shower.

A lukewarm bath with Epsom salt, mineral oil, milk, or olive oil can soothe the itching and infiltrate scales and plaques. Oatmeal baths can also be very helpful and soothing for plaque psoriasis.

Be sure that the water is not hot. Hot water can cause more irritation.

Moisturize immediately after your bath for double benefits.

Light therapy involves exposing your skin to ultraviolet light under the supervision of a doctor.

Ultraviolet light can help slow the growth of skin cells triggered by psoriasis. This therapy often requires consistent and frequent sessions. Sitting in the sun for 10 to 15 minutes can also help reduce plaques.

However, too much sunlight and tanning beds arent the best options as they can also increase your risk of skin cancer.

Light therapy should always be done under the supervision of a doctor.

Any chronic condition like psoriasis can be a source of stress, which in turn can worsen psoriasis symptoms.

In addition to reducing stress whenever possible, consider incorporating stress-reducing practices such as yoga and meditation.

Alcohol is a trigger for many people who have psoriasis.

A study in 2015 found an increased risk of psoriasis among women who drank nonlight beer. Those who drank at least five nonlight beers per week were nearly twice as likely to develop psoriasis compared to women who didnt drink.

Herbs are commonly used to treat many conditions.

Turmeric has been found to help minimize psoriasis flare-ups. It can be taken in pill or supplement form, or sprinkled on your food.

Talk to your doctor about the potential benefits for you.

Avoid tobacco. Smoking may increase your risk of psoriasis.

If you already have psoriasis, it can make your symptoms more severe.

Being overweight or obese puts you at a greater risk of developing psoriasis. Obesity is also associated with more severe psoriasis symptoms. Studies have found that losing weight can help improve these symptoms.

Here are some tips for losing weight:

There isnt a single answer for keeping the symptoms of psoriasis at bay. What works for one person may not work for another.

Some treatment options may have negative side effects for preexisting conditions other than psoriasis.

While these remedies for psoriasis may help with mild cases, prescription therapy is required for more severe cases. Talk to your doctor before seeking treatment on your own.

Read this article in Spanish.

A dermatologist can treat the thick, red, scaly patches of skin (also known as plaques) from psoriasis. They can also treat other parts of your body that moderate to severe psoriasis may affect, such as your scalp and nails. Consider checking with your dermatologist when you experience a flare or worsening symptoms.

Nearly a third of people with psoriasis develop a condition called psoriatic arthritis. This can cause swollen, stiff, or painful joints. A rheumatologist can determine if you have psoriatic arthritis and prescribe treatments to control your symptoms. This type of doctor specializes in treating arthritis and other musculoskeletal disorders.

Psoriasis has been linked to other health conditions, such as lymphoma, heart disease, diabetes, and high blood pressure. A primary care doctor can help you find ways to reduce your risk of other conditions and improve your overall health. They can also screen you for early warning signs of psoriasis complications and refer you to a specialist, if necessary.

While psoriasis has no cure, it can be treated with a variety of prescription medications (like immunosuppressive drugs) and over-the-counter drugs (such as topical ointments). A pharmacist can provide information and tips on following your treatment plan and can make sure your medications are safe to take together. They can also answer questions or address concerns about your medications.

Stress has been shown to be a trigger for psoriasis flares. A psychologist, licensed professional counselor, or clinical social worker can help you develop personalized ways to manage stress. Self-care techniques such as breathing exercises, journaling, meditation, yoga, and stretching can also help you ease stress.

Cutting back on foods that trigger psoriasis flares can help reduce symptoms. A dietitian can help you develop a nutritious eating plan that may potentially reduce inflammation in the body. They can also help you maintain a healthy weight to avoid obesity and reduce your risk of psoriasis-related complications, such as diabetes and heart disease.

Originally posted here:
12 Ways to Treat Psoriasis at Home - Healthline

DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value  Forbes

Excerpt from:
DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes